SRR1420493
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.569
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.387
- PROTEIN_SECRETION+0.312
- FATTY_ACID_METABOLISM+0.291
- BILE_ACID_METABOLISM+0.256
- PANCREAS_BETA_CELLS+0.250
- ADIPOGENESIS+0.221
- KRAS_SIGNALING_DN+0.212
- SPERMATOGENESIS+0.206
- MTORC1_SIGNALING+0.169
Top 10 suppressed
- G2M_CHECKPOINT-0.386
- E2F_TARGETS-0.378
- WNT_BETA_CATENIN_SIGNALING-0.368
- TNFA_SIGNALING_VIA_NFKB-0.364
- TGF_BETA_SIGNALING-0.347
- IL6_JAK_STAT3_SIGNALING-0.332
- MYC_TARGETS_V2-0.306
- MITOTIC_SPINDLE-0.274
- INTERFERON_GAMMA_RESPONSE-0.247
- NOTCH_SIGNALING-0.246
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1413959 | GTEX | — | 0.925 |
| 2 | SRR1318426 | GTEX | — | 0.892 |
| 3 | SRR1437306 | GTEX | — | 0.878 |
| 4 | SRR1101421 | GTEX | — | 0.877 |
| 5 | SRR1415095 | GTEX | — | 0.875 |
| 6 | SRR604050 | GTEX | — | 0.859 |
| 7 | SRR1474466 | GTEX | — | 0.845 |
| 8 | SRR660969 | GTEX | — | 0.837 |
| 9 | SRR1471817 | GTEX | — | 0.835 |
| 10 | SRR1420984 | GTEX | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.569 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.387 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.312 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.291 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.256 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.221 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.212 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.206 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.169 | Inavolisib | — uncovered |
| MYOGENESIS | 0.169 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.115 | Idelalisib | — uncovered |
| PEROXISOME | 0.104 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.095 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.037 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.008 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.007 | Idelalisib | — uncovered |